Here we report the formation of filamentous tau aggregations having a ␤-sheet structure in transgenic mice expressing mutant human tau. These mice contain a tau gene with a mutation of the frontotemporal dementia parkinsonism (FTDP-17) type, in which valine is substituted with methionine residue 337. The aggregation of tau in these transgenic mice satisfies all histological criteria used to identify NFTs common to human neurodegenerative diseases. These mice, therefore, provide a preclinical model for the testing of therapeutic drugs for the treatment of neurodegenerative disorders that exhibit NFTs.
INTRODUCTION
Neurofibrillary tangles (NFTs) are neuronal inclusions of microtuble-binding protein tau and are composed of phosphorylated and ubiquitinated tau aggregations that form ␤-pleated sheet structures. Given this, NFT-bearing neurons are ubiquitin-and phosphorylation dependent tau-immunoreactive, argyrophilic, Congo red birefringent, and thioflavin-S reactive. Tau dysfunction and filamentous tau aggregates are key markers of neurodegenerative pathologies that display NFTs, which is the most common pathway leading to degeneration of neurons in several neurodegenerative diseases, including Alzheimer's disease (AD). In the brains of patients with AD, tau fibrils form abundant paired helical filaments (PHF) and straight tubules. Discovery of the molecular mechanisms of NFT formation may lead to more insight about events occurring during neurodegeneration in AD. In frontotemporal dementia parkinsonism 17 (FTDP-17), genetic studies revealed that the causative factor is a tau gene containing mutations in its exons and introns. Patients possessing this mutation exhibit NFTs and loss of neurons. Thus, tau abnormalities cause the formation of NFTs, which in turn leads to neurodegeneration.
In light of the important link between NFT formation and neurodegenerative diseases, a concerted effort has been made to produce tau transgenic mice. Intronic mutation and some missense mutations of the tau gene alter the splicing and increase the expression of the tau transcript within exon 10, which encodes 4 microtubule binding repeat tau (Goedert et al., 1998; Lee & Trojanowski, 1999) . Based on this evidence, three lines of transgenic mice expressing human tau have been produced (Brion et al., 1999; Gotz et al., 1995; Ishihara et al., 1999) . Neurons from mice of these lines express a 2-to 10-fold increase in tau, and display tau inclusions. However, none of these exhibit the Congo
